Inhibitor Therapeutics's market cap is currently ―. The company's EPS TTM is $-0.017; its P/E ratio is -5.51; Inhibitor Therapeutics is scheduled to report earnings on May 1, 2018, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	-	-	-	-	$ 0.00
Gross Profit	-	-	-	-	-
EBIT	$ -664.76K	$ -654.52K	$ 629.72K	$ 12.42M	$ -69.99K
EBITDA	$ -664.76K	$ -654.52K	$ 629.72K	$ 12.42M	$ -69.99K
Net Income Common Stockholders	$ -664.80K	$ -654.52K	$ 719.85K	$ 12.32M	$ -128.10K
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 9.54M	$ 10.10M	$ 10.78M	$ 11.95M	$ 53.06K
Total Assets	$ 9.61M	$ 10.16M	$ 10.84M	$ 11.98M	$ 63.12K
Total Debt	$ 0.00	$ 0.00	$ 0.00	$ 411.00K	$ 411.00K
Net Debt	$ -9.54M	$ -10.10M	$ -10.78M	$ -11.54M	$ 357.94K
Total Liabilities	$ 3.16M	$ 3.04M	$ 3.08M	$ 3.68M	$ 4.09M
Stockholders Equity	$ 6.45M	$ 7.11M	$ 7.76M	$ 8.30M	$ -4.02M
Cash Flow	-
Free Cash Flow	$ -562.71K	$ -682.61K	$ -757.28K	$ 11.90M	$ -51.89K
Operating Cash Flow	$ -562.71K	$ -682.61K	$ -757.28K	$ 11.90M	$ -51.89K
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	-	-	$ -411.00K	-	$ 80.00K

Currency in USD

Inhibitor Therapeutics Earnings and Revenue History

Income Statement >

Inhibitor Therapeutics Debt to Assets

Balance Sheet >

Inhibitor Therapeutics Cash Flow

Cash Flow >

Inhibitor Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing